Possible Benefits of Faecalibacterium prausnitzii for Obesity-Associated Gut Disorders
Возможная польза Faecalibacterium prausnitzii при заболеваниях кишечника, связанных с ожирением
2021-12-02
SCID: 54.1/u484j6pq
Discuss with AI
Faecalibacterium prausnitziibutyrate-producing bacteriagut microbiotainsulin resistancemicrobial dysbiosis
Figures from the paper
Abstract (AI)
Metabolic disorders are an increasing concern in the industrialized world. Current research has shown a direct link between the composition of the gut microbiota and the pathogenesis of obesity and diabetes. In only a few weeks, an obesity-inducing diet can lead to increased gut permeability and microbial dysbiosis, which contributes to chronic inflammation in the gut and adipose tissues, and to the development of insulin resistance. In this review, we examine the interplay between gut inflammation, insulin resistance, and the gut microbiota, and discuss how some probiotic species can be used to modulate gut homeostasis. We focus primarily on Faecalibacterium prausnitzii , a highly abundant butyrate-producing bacterium that has been proposed both as a biomarker for the development of different gut pathologies and as a potential treatment due to its production of anti-inflammatory metabolites.
Key Findings
1
Faecalibacterium prausnitzii is a highly abundant butyrate-producing bacterium proposed as a biomarker for gut pathologies and a potential probiotic treatment.
2
Faecalibacterium prausnitzii may help restore gut homeostasis through production of anti-inflammatory metabolites.
3
Gut dysbiosis and increased permeability contribute to chronic inflammation in gut and adipose tissues and promote insulin resistance.
4
Gut microbiota composition is directly linked to the pathogenesis of obesity and diabetes.
5
Obesity-inducing diets can rapidly increase gut permeability and cause microbial dysbiosis within a few weeks.
Research Object
Faecalibacterium prausnitzii in obesity-associated gut disorders
Research Subject
Its role in gut homeostasis, inflammation, insulin resistance, and gut pathology through production of anti-inflammatory metabolites
Publication Details
Publication Date
2021-12-02
Journal
Publisher
ISSN
Cited by
156
Open access PDF
Access Type
Author Information
Download PDF
Subscribe to digest